Procept BioRobotics (PRCT) reported a Q1 net loss Thursday of $0.45 per diluted share, narrowing from a loss of $0.51 a year earlier.
Analysts polled by FactSet expected a loss of $0.49.
Revenue for the quarter ended March 31 was $69.2 million, up from $44.5 million a year earlier.
Analysts surveyed by FactSet expected $65.4 million.
For 2025, the surgical robotics company lifted its revenue guidance to $323 million from the previous $320 million. Analysts polled by FactSet expect $322 million.
Shares of the company were up more than 2% in recent premarket activity.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。